Cargando…

Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review

INTRODUCTION: Optimal anticoagulation therapy is essential for the prevention of thrombotic and hemorrhagic complications in pediatric patients supported with extracorporeal membrane oxygenation (ECMO). Recent data have demonstrated bivalirudin has the potential to surpass and replace heparin as the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valdes, Carlos A., Sharaf, Omar M., Bleiweis, Mark S., Jacobs, Jeffrey P., Mumtaz, Mohammed, Sharaf, Ramy M., Jeng, Eric I., Peek, Giles J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043325/ https://www.ncbi.nlm.nih.gov/pubmed/36999064 http://dx.doi.org/10.3389/fmed.2023.1137134

Ejemplares similares

Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation
por: Ranucci, Marco, et al.
Publicado: (2011)

Extracorporeal Membrane Oxygenation Complications in Heparin- and Bivalirudin-Treated Patients
por: Giuliano, Katherine, et al.
Publicado: (2021)

Superiority of bivalirudin over heparin anticoagulation therapy for extracorporeal membrane oxygenation? Too early to draw conclusions
por: Gu, Jie, et al.
Publicado: (2023)

The Efficacy and Safety of Bivalirudin Versus Heparin in the Anticoagulation Therapy of Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis
por: Ma, Min, et al.
Publicado: (2022)

Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19
por: Seelhammer, Troy G., et al.
Publicado: (2021)

Management of Bivalirudin Anticoagulation Therapy for Extracorporeal Membrane Oxygenation in Heparin-Induced Thrombocytopenia: A Case Report and a Systematic Review
por: Zhong, Han, et al.
Publicado: (2020)

Periprocedural anticoagulation in transcatheter aortic valve replacement: Heparin vs bivalirudin
por: Minhas, Abdul Mannan Khan, et al.
Publicado: (2017)

Bivalirudin or heparin: which anticoagulation strategy for critically ill cardiac surgery patients?
por: Pappalardo, F, et al.
Publicado: (2014)

Bivalirudin Anticoagulation in Extracorporeal Membrane Oxygenation (ECMO) for Severe Coronaviral Disease (COVID-19) Related Acute Respiratory Distress Syndrome (ARDS)
por: Kumar, S., et al.
Publicado: (2022)

Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity
por: Stephenne, Xavier, et al.
Publicado: (2012)

Is it time to switch to bivalirudin for ECMO anticoagulation?
por: Navaei, Amir, et al.
Publicado: (2023)

The Emerging Role of Bivalirudin for Therapeutic Anticoagulation in Patients With Coronavirus Disease 2019 Requiring Extracorporeal Membrane Oxygenation Support: Is It Time to Change the Routine Practice?
por: Tahan, Mohamed R. El
Publicado: (2022)

Bivalirudin for cardiopulmonary bypass in a patient with heparin allergy
por: Boysan, Emre, et al.
Publicado: (2023)

Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients
por: Chai, Lina, et al.
Publicado: (2023)

Selection of an Aptamer Antidote to the Anticoagulant Drug Bivalirudin
por: Martin, Jennifer A., et al.
Publicado: (2013)

Durable biventricular assist device support for 1212 days as a bridge to heart transplantation
por: Sharaf, Omar M, et al.
Publicado: (2023)

Anticoagulation Therapy during Extracorporeal Membrane Oxygenator Support in Pediatric Patients
por: Cho, Hwa Jin, et al.
Publicado: (2017)

Context-Responsive Anticoagulation Reduces Complications in Pediatric Extracorporeal Membrane Oxygenation
por: Lin, John C., et al.
Publicado: (2021)

Anticoagulation on extracorporeal membrane oxygenation (ECMO)
por: Khilnani, Praveen
Publicado: (2017)

Venovenous extracorporeal membrane oxygenation in obese patients
por: Javidfar, Jeffrey, et al.
Publicado: (2021)

Successful intraprocedural anticoagulation with bivalirudin during pulmonary vein isolation in a patient with known heparin-induced thrombocytopenia type II
por: Bellmann, Barbara, et al.
Publicado: (2016)

Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides
por: Kapur, Navin K., et al.
Publicado: (2012)

EFFECT OF HEPARIN AND BIVALIRUDIN ON THE KINETICS OF CLOT FORMATION: VISCOELASTIC COAGULATION TESTING
por: Hasija, Suruchi, et al.
Publicado: (2017)

Bivalirudin versus heparin in primary PCI: clinical outcomes and cost analysis
por: Deharo, Pierre, et al.
Publicado: (2018)

Primary bivalirudin anticoagulation for patients with an implantable ventricular assist device
por: Pieri, M, et al.
Publicado: (2014)

Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
por: Trigonis, Russell, et al.
Publicado: (2022)

Endogenous glycosaminoglycan anticoagulation in extracorporeal membrane oxygenation
por: MacLaren, Graeme, et al.
Publicado: (2014)

Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patients
por: Ranucci, Marco, et al.
Publicado: (2014)

The Changing Landscape of Anticoagulation in Pediatric Extracorporeal Membrane Oxygenation: Use of the Direct Thrombin Inhibitors
por: Neunert, Cindy, et al.
Publicado: (2022)

Bivalirudin Versus Heparin During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
por: Patel, Hiten, et al.
Publicado: (2019)

How to manage anticoagulation during extracorporeal membrane oxygenation
por: Levy, Jerrold H., et al.
Publicado: (2022)

Management of Anticoagulation during Extracorporeal Membrane Oxygenation in Children
por: Chegondi, Madhuradhar, et al.
Publicado: (2022)

Low molecular weight heparin versus unfractioned heparin for anticoagulation during perioperative extracorporeal membrane oxygenation: A single center experience in 102 lung transplant patients
por: Gratz, Johannes, et al.
Publicado: (2020)

Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO‐3 randomized trial
por: Zilberszac, Robert, et al.
Publicado: (2019)

Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation
por: Lüsebrink, Enzo, et al.
Publicado: (2023)

Successful extended use of Impella 5.5 as a bridge to heart transplantation
por: Sharaf, Omar M, et al.
Publicado: (2023)

Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention
por: Centurión, Osmar Antonio
Publicado: (2016)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation
por: Burstein, Barry, et al.
Publicado: (2019)

Sodium alginate-hydrogel coatings on extracorporeal membrane oxygenation for anticoagulation
por: Gao, Wenqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rmg8bdg7dr1a6121qb3cak5vrs